Redeye returns with an update following Alligator Bioscience’s Q4 earnings release.
Redeye briefly comments on Alligator Bioscience announcing the outcome of its rights issue, with 64.
Alligator Bioscience has secured additional subscription and top guarantee commitments for its SEK120m rights issue, increasing the guarante...
Today, Monday, 1 December, is the ex-rights date for the preferential rights issue, marking the first day of trading when the stock price sh...
Redeye provides an updated valuation of Alligator as the subscription price in the rights issue, SEK0.
Redeye comments on Alligator presenting new data on mitazalimab at SITC 40th Anniversary Annual Meeting last week.
We open up for questions on our Q3 update.
Redeye reviews Alligator Bioscience’s Q3 report 2025.
Redeye comments on the phase I data generated from a phase I study combining MesoPher with mitazalimab.
Redeye believes the data is solid and in line with previous readouts.
Redeye is pleased with TO13’s preliminary subscription rate of 91%.
This morning, Alligator announced the launch of a new investigator-sponsored phase II/III trial with mitazalimab in biliary tract cancer.
Redeye comments on Alligator Bioscience's second quarter report 2025.
Redeye comments on Alligator Bioscience’s recent interactions with the FDA and the EMA.
Redeye is satisfied with TO12's preliminary subscription rate of 71%.
Redeye provides a brief comment on the news that 85% of the TO 12 warrant program has been secured and that the outstanding loan with Fenja ...
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition for starting phase III.
Redeye comments on Alligator's first quarter 2025, during which a rights issue of gross SEK150m was conducted and new positive 24-month data...
Redeye comments on the reverse split and new conditions of TO12.
Redeye comments on Alligator Bioscience’s 24-month survival numbers, which are superior to historical controls.
Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54%.
Redeye comments on Alligator Bioscience's end of phase II meeting with the American regulatory authority (the FDA).
Redeye provides its thoughts on the rights issue.
Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phase III study of mitazalimab in pancreatic...
Redeye discusses Alligator Bioscience's rights issue announced on 2 January.
Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being developed by the latter under a licensing agreem...
Redeye comments on the new ALG.APV-527 phase I data.
Redeye comments on Alligator's Q3 report. The main event since our last update was the ALG.
Redeye comments on the positive ALG.APV-527 data presented at ESMO this weekend.
Redeye comments on Alligators Q2 report and updates its base case.
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a phase II study of mitazalimab combined wit...
Redeye comments on the start of a new phase I study of mitazalimab in local pancreatic cancer.
Redeye comments on Alligator Bioscience's Q1 report, including the sub-optimal funding situation after the rights issue and upcoming catalys...
Redeye comments on the outcome in the rights issue, with a subscription rate of 71%.
Redeye comments on the interim readout of the phase I study of ALG.
Redeye reviews Alligator Bioscience’s fourth quarter and the rights issue announced on Thursday evening.
Redeye increases its base case after the positive topline results from OPTIMIZE-1, the phase II study of mitazalimab in pancreatic cancer.
Redeye comments on Alligator’s CMD on 1 December, 2023.
Redeye comments on Alligator’s Q3 report. The OPTIMIZE-1 topline readout will be a major catalyst and is expected in early Q1 2024.
Redeye comments on the outcome of the TO6 warrants subscription.
Redeye has a positive view of mitazalimab obtaining orphan drug designation, which we discuss briefly.
Redeye is convinced by the second interim readout of mitazalimab in which the objective response rate was 44% based on 57 patients.
Redeye comments on the second interim readout with 57 evaluable patients.
Redeye comments on Alligator Bioscience following the rights issue and Q1 report.
Redeye resumes its coverage of Alligator following the rights issue adding SEK 181m (before transaction costs) to the company's balance shee...
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results (an ORR of 52%) in the int...
Redeye considers Mitazalimab’s results in the first interim readout of the phase II trial presented yesterday evening to be very promising, ...
Redeye comments on Alligator's announcement of the initiation of a second bispecific program within the Orion collaboration.
Redeye discusses events and financial results in Q3 2022.
Redeye comments on Alligator’s successful conclusion of the phase I trial with ATOR-1017.
Redeye comments on Alligator Bioscience’s second quarter report.
Redeye is optimistic about ATOR-1017 following new data released by Alligator Bioscience at ASCO 2022.
Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later this year.
Redeye comments on Alligator Bioscience’s first quarter report.
Redeye finds it reassuring that mitazalimab is safe and tolerable at the highest dose tested in OPTIMIZE-1 in pancreatic cancer.
Redeye comments on Alligator Bioscience’s end-of-year report.
Redeye provides a brief comment on the news that Alligator is exploring financing alternatives.
Redeye comments on the research collaboration with Orion and sees a positive impact on our fair value estimate.
Redeye provides an initial take on Alligator’s Q2 report.
